Vaderis Therapeutics
4 known investors
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.
Investors · 4
Funding
SEC filings, press & company announcements$152M disclosed across 1 round · 2026
- $152MSeries BAug 2026 · 4 sources
EQT Life Sciences, Goldman Sachs Asset Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Fierce Biotech Fundraising Tracker '26: Encoded finagles $275M series F; Solstice rises with $225Mfiercebiotech.com · Sep 2026
VC funding deals: Castelion, AuraGxP, Vaderis Therapeutics - InfotechLeadinfotechlead.com · Aug 2026Frequently asked questions
- What does Vaderis Therapeutics do?
- Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments. The company is led by scientists and clinicians focused on creating therapeutic options for patients with underserved rare diseases.
- Who are Vaderis Therapeutics's investors?
- Vaderis Therapeutics's investors include Droia Ventures, Medicxi, EQT Life Sciences, Goldman Sachs.
- How much funding has Vaderis Therapeutics raised?
- Vaderis Therapeutics has disclosed $152M raised across 1 round.